The present invention relates to a pharmaceutical composition for oral administration comprising a non-bile farnesoid X receptor (FXR) agonist 2-[(1R,3R,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and at least one lipid excipient； to a capsule for oral administration comprising said pharmaceutical composition； to the use of said pharmaceutical composition for the treatment of a FXR mediated disorder or condition； and to a process for preparing said pharmaceutical composition.本發明係關於用於經口投與之醫藥組合物，其包含非膽汁法尼醇X受體(FXR)促效劑2-[(1R,3R,5S)-3-({5-環丙基-3-[2-(三氟甲氧基)苯基]-1,2-噁唑-4-基}甲氧基)-8-氮雜二環[3.2.1]辛-8-基]-4-氟-1,3-苯并噻唑-6-甲酸或其醫藥上可接受之鹽及至少一種脂質賦形劑；係關於包含該醫藥組合物之用於經口投與之膠囊；係關於該醫藥組合物用於治療FXR介導之病症或病況之用途；及係關於製備該醫藥組合物之方法。
